# Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study

Source: https://onco.cc/key-papers/paper-steward-thyroseq-v3-indeterminate-nodules-jama-oncol-2019/  
OnCo record `paper-steward-thyroseq-v3-indeterminate-nodules-jama-oncol-2019` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A prospective blinded study showing how well the ThyroSeq v3 test sorted thyroid nodules whose needle sample was uncertain.

## Summary

The classifier had 94 per cent (95% CI 86 to 98) sensitivity and 82 per cent (95% CI 75 to 87) specificity, with a negative predictive value of 97 per cent.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: JAMA Oncology
- Year: 2019
- DOI: 10.1001/jamaoncol.2018.4616
- Authors: Steward DL, Carty SE, Sippel RS, et al.
- Findings: Sensitivity 94%, specificity 82%, negative predictive value 97%.
- What it means: A negative result makes cancer unlikely enough that some people can avoid diagnostic surgery.
- Caveats: Predictive values depend on how common cancer is in the population tested.

## Sources

- Steward et al., JAMA Oncol 2019: https://doi.org/10.1001/jamaoncol.2018.4616
- PubMed: https://pubmed.ncbi.nlm.nih.gov/30419129/

## Connected records

- cancers: [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Thyroid nodule FNA, Bethesda cytology & molecular classifiers](https://onco.cc/technologies/thyroid-fna-molecular/)
- drugs: [ThyroSeq v3 Genomic Classifier](https://onco.cc/drugs/thyroseq/)
- terms: [Biomarker](https://onco.cc/terms/biomarker/)

---
JSON: https://onco.cc/api/v1/entities/paper-steward-thyroseq-v3-indeterminate-nodules-jama-oncol-2019.json